论文部分内容阅读
以免疫组化ＡＢＣ法检测乳腺癌ｃｅｒｂＢ２、表皮生长因子受体（ＥＧＦＲ）基因蛋白表达，研究其与预后的关系。结果：ｃｅｒｂＢ２、ＥＧＦＲ阳性表达率各为３８．５％（２５／６５）和４３．１％（２８／６５）。除ＥＧＦＲ表达与ＥＲ、ＰＲ负相关外，ｃｅｒｂＢ２、ＥＧＦＲ表达与临床预后因素无相关性，二者之间亦无相关性。ｃｅｒｂＢ２或ＥＧＦＲ阳性组术后生存显著差于阴性组（Ｐ＜０．０１）；多因素分析二者是显著影响乳腺癌预后的两个重要因素；ｃｅｒｂＢ２可判别出Ⅰ、Ⅱ期及淋巴结无转移患者预后差者；二者均阳性组与ｃｅｒｂＢ２阳性或ＥＧＦＲ阳性组术后生存有极显著性差别（Ｐ＜０．００１）。提示ｃｅｒｂＢ２与ＥＧＦＲ可以成为乳腺癌有效的独立的预后指标，而且ｃｅｒｂＢ２优于ＥＧＦＲ，但二者联合检测，可提高其预后价值。
Immunohistochemical ABC method was used to detect the expression of c erbB 2 and epidermal growth factor receptor (EGFR) gene in breast cancer, and its relationship with prognosis was studied. RESULTS: The positive expression rates of c-erbB-2 and EGFR were 38.5% (25/65) and 43.1% (28/65) respectively. Except that EGFR expression was negatively correlated with ER and PR, there was no correlation between c-erbB-2 and EGFR expression and clinical prognostic factors, and there was no correlation between them. The survival rate of cerbB2 or EGFR positive group was significantly lower than that of the negative group (P<0.01). Multivariate analysis was two important factors that significantly affected the prognosis of breast cancer; cerbB2 could be distinguished. Patients with stage I and II metastases and those with no lymph node metastasis had poor prognosis. There was a significant difference in postoperative survival between positive and c-erbB-2-positive or EGFR-positive groups (P<0.001). It is suggested that c erbB 2 and EGFR can be effective independent prognostic indicators of breast cancer, and c erbB 2 is better than EGFR, but the combined detection of both can increase its prognostic value.